sphingotest® vr-hGH

Risk Prediction of Incident Cardiovascular Disease
sphingotec offers the vascular risk human Growth Hormone biomarker (vr-hGH) for the risk prediction of incident cardiovascular disease in male subjects. It is imperative to identify and predict vascular risk in the general population early on. The biomarker vr-hGH developed by sphingotec enables an early intervention to reduce vascular risk.


sphingotest pro-NT

sphingotest® pro-NT

Risk assessment of cardiovascular disease in women
The hormone Neurotensin has now been discovered as a new biomarker with the aid of which the individual risk of cardiovascular disease in women can be predicted. In order to obtain such a prognosis of risk, the concentration of Proneurotensin, a fragment of the precursor molecule of Neurotensin, is determined by means of a simple blood test (sphingotest® pro-NT).



sphingotest® pro-NT/pro-ENK

Simple detection in the risk of breast cancer
In the United States 1 in every 8 women develops breast cancer during her lifetime; with approx. 230,000 cases of invasive breast cancer expected to be diagnosed each year. Over 88% of breast cancer cases occur at ages 45+. We know that the earlier the development of this cancer is detected, the higher the chances of treating it successfully.



sphingotest® bio-ADM

Biomarker for Guidance of Vasopressor Administration in Acute Diseases
bio-ADM (bioactive adrenomedullin) is a soluble peptide hormone with a molecular weight of approximately 6kDa. Mainly released by endothelial cells, its biological function is to control vasodilation, an important regulator of blood pressure and organ perfusion. This marker predicts and provides a diagnosis for circulation dysfunction.


Flyer-bio-ADM in AHF Flyer-bio-ADM in Shock


sphingotest® penKid

Biomarker for Identification and Prediction of Kidney Failure in Acute Disease
penKid is associated with severity of Acute Kidney Injury not being elevated by inflammation. The majority of patients without kidney failure are within normal range, despite inflammation whereas NGAL, as one example of an inflammation-dependent marker, is elevated above the normal range for almost all patients.